ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2020年06月23日 16時00分
Source:
Eisai
エーザイ、新株予約権証券の発行登録書の提出について
東京, 2020年06月23日 - (JCN Newswire) - 当社は、本日、「当社企業価値・株主共同の利益の確保に関する対応方針」(以下、本対応方針) に基づき、新株予約権証券の発行登録書を関東財務局に提出しました。本発行登録書の概要は下記の通りです。なお、本件は2019年6月21日に提出した発行登録書の期間(2019年7月1日から2020年6月30日)終了に対応するものです。
1.募集有価証券の種類:新株予約権証券
2.発行予定期間:発行登録の効力発生予定日から1年を経過する日まで(2020年7月1日から2021年6月30日)
3.募集方法:株主割当
4.発行予定額:8億円(上記は、新株予約権証券の発行価額の総額(無償)に新株予約権の行使に際して払い込むべき金額の合計額を合算した金額)
2020年6月19日に開催した取締役会において、社外取締役独立委員会より本対応方針を継続する旨の提案がなされ、審議の結果、提案通りに決議しました。本発行登録は機動的な株主割当による新株予約権発行を可能とするものです。
本対応方針の内容は、こちらをご参照ください。
(
https://www.eisai.co.jp/news/2020/pdf/news202028pdf.pdf
)
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2020/news202030.html
概要:エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Mitsubishi Power Advances Thailand's Energy Development with Completion of 1,400MW Combined Cycle Hin Kong Power Plant
Jan 21, 2025 16:24 JST
DENSO Exhibits at Bharat Mobility Global Expo 2025, New Delhi
Jan 20, 2025 20:26 JST
Hitachi Acquires a Sales and Maintenance Service Company for Large Motors in the United States
Jan 20, 2025 15:07 JST
Suzuki's First BEV "e VITARA" Adopts eAxle
Jan 20, 2025 13:58 JST
Honda Presents the World Premier of BF300 Large-size Outboard Motor at the Dusseldorf Boat Show 2025
Jan 20, 2025 11:36 JST
TOYOTA GAZOO Racing begins WRC title bid with a legendary challenge
Jan 17, 2025 19:53 JST
Mitsubishi Corporation and JOGMEC Announce Investment in eFuels provider Infinium
Jan 17, 2025 14:35 JST
NEC Listed on the World Index and Asia Pacific Index of Dow Jones Sustainability Indices (DJSI)
Jan 17, 2025 12:47 JST
Mitsubishi Power Reinforces Commitment to Saudi Arabia's Sustainable Energy Future at Saudi Aramco's IKTVA Forum 2025
Jan 16, 2025 16:56 JST
JCB and DOJO Partner to Help Cardmembers Enjoy a More Seamless Payment Experience
Jan 16, 2025 11:00 JST
MHI Delivers 60 Cars for the Nippori-Toneri Liner Model 330
Jan 15, 2025 16:38 JST
JCB and Taiwan Rakuten Card Launch New JCB Panda Card
Jan 15, 2025 15:00 JST
Fujitsu, Resona Bank and Saitama Resona Bank launch new web service to simplify home-buying process
Jan 15, 2025 13:13 JST
FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Jan 15, 2025 10:03 JST
18th Asian Financial Forum wraps up successfully
Jan 14, 2025 20:56 JST
Honda Civic Hybrid Named 2025 North American Car of the Year, Making Civic the Most Honored Model in the History of the Award
Jan 13, 2025 17:07 JST
Galaxy Payroll: Driving Innovation in Human Resources Management
Jan 10, 2025 23:35 JST
Honda 2025 Motorsports Program Overview
Jan 10, 2025 20:26 JST
TOYOTA GAZOO Racing Exhibiting at Tokyo Auto Salon 2025
Jan 10, 2025 18:38 JST
Mazda Introduce the All-NEW "Mazda6" Battery EV in Europe
Jan 10, 2025 17:27 JST
More Latest Release >>
Related Release
FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease
1/15/2025 10:03:00 AM JST
Elucidation of part of the Mechanism by which Lecanemab Slows the Progression of Alzheimer's Disease
1/7/2025 9:14:00 AM JST
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
12/23/2024 5:22:00 PM JST
Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia
12/11/2024 2:45:00 PM JST
"LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
12/5/2024 11:22:00 AM JST
LEQEMBI (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea
11/28/2024 4:26:00 PM JST
Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan
11/26/2024 3:50:00 PM JST
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
11/20/2024 11:51:00 AM JST
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
11/20/2024 10:24:00 AM JST
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
11/15/2024 5:33:00 PM JST
More Press release >>